The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...
Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a ...
Zacks.com on MSN3d
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which ...
Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...
India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...
Lundbeck is to acquire Longboard for $2.6bn equity value in a move set to enhance its capabilities within neuro-rare ...
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an ...
On 18 September 2024, the Honourable Justice Jackman, in his capacity as a Deputy President of the Administrative Appeals Tribunal (AAT), granted Sandoz a licence pursuant to section 223(9) of the ...
(Reuters) -H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ...
H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...
Baker McKenzie advise Lundbeck in $2.6B Longboard Pharmaceuticals acquisition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback